| Literature DB >> 35849686 |
Anind Dey1, Mayank Goel2, Zongqi Xia3, Prerna Chikersal2, Shruthi Venkatesh3, Karman Masown3, Elizabeth Walker3, Danyal Quraishi3.
Abstract
BACKGROUND: The COVID-19 pandemic has broad negative impact on the physical and mental health of people with chronic neurological disorders such as multiple sclerosis (MS).Entities:
Keywords: COVID-19; algorithm; behavior change; depression; digital phenotyping; disability; exercise; fatigue; feature selection; fitness; health outcome; isolation; mHealth; machine learning; mental health; mobile health; mobile sensing; movement; multiple sclerosis; neurological disorder; physical activity; predict; sensing; sensor; sleep; tiredness; tracker
Year: 2022 PMID: 35849686 PMCID: PMC9407162 DOI: 10.2196/38495
Source DB: PubMed Journal: JMIR Ment Health ISSN: 2368-7959
Figure 1Data processing and analysis pipeline. (A) Machine learning pipeline for predicting depression (Patient Health Questionnaire-9 [PHQ-9]), global MS symptom burden (Multiple Sclerosis Rating Scale—Revised [MSRS-R]), fatigue (Modified Fatigue Impact Scale-5 [MFIS-5]), and sleep quality (Pittsburgh Sleep Quality Index [PSQI]) using passive sensors from smartphones and fitness trackers. (B) For each sensor during the pre–stay-at-home period and the stay-at-home period, each feature was extracted from 15 time slices. The pre–stay-at-home features were subtracted from the stay-at-home features to obtain the behavior change features. First, raw data from the device sensor were preprocessed and then filtered by a time-of-the-day epoch and a days-of-the-week option. Features were then extracted from the selected raw data.
Study participant characteristics.
| Variable | Value | |
|
|
| |
|
| Female | 48 (86) |
|
| Male | 8 (14) |
|
|
| |
|
| White | 51 (91) |
|
| African or African American | 5 (9) |
|
|
| |
|
| Non-Hispanic or Latino | 55 (98) |
|
| Hispanic or Latino | 1 (2) |
| Age (years), median (IQR) | 43.5 (37-52) | |
| Time elapsed (years) from age of first neurological symptom | 13.0 (6.7-17.4) | |
| PDDSa score at start of study, median (IQR) | 1 (0-3) | |
|
|
| |
|
| Higher efficacy | 38 (68) |
|
| Standard efficacy | 12 (21) |
|
|
| |
|
| Not diagnosed with clinical depression before study enrollment | 39 (70) |
|
| Diagnosed with clinical depression before study enrollment | 17 (30) |
|
|
| |
|
| Not taking medication for depression before study enrollment | 39 (70) |
|
| Taking medication for depression before study enrollment | 17 (30) |
|
|
| |
|
| Not receiving nonmedication therapy for depression before study enrollment | 52 (93) |
|
| Receiving nonmedication therapy for depression before study enrollment | 4 (7) |
|
|
| |
|
| PHQ-9b (depression) | 3.7 (0.0-7.4) |
|
| MSRS-Rc (global MSd symptom burden) | 7.5 (3.4-10.3) |
|
| MFIS-5e (fatigue) | 8.0 (4.6-11.0) |
|
| PSQIf (sleep quality) | 11.0 (7.8-14.3) |
aPDDS: Patient Determined Disease Steps.
bPHQ-9: Patient Health Questionnaire-9.
cMSRS-R: Multiple Sclerosis Rating Scale—Revised.
dMS: multiple sclerosis.
eMFIS-5: Modified Fatigue Impact Scale-5.
fPSQI: Pittsburgh Sleep Quality Index.
Figure 2Correlations among the 4 clinically relevant patient-reported outcomes in this study. For all correlations, P<.001 (N=56). MFIS-5: Modified Fatigue Impact Scale-5; MSRS-R: Multiple Sclerosis Rating Scale—Revised; PHQ-9: Patient Health Questionnaire-9; PSQI: Pittsburgh Sleep Quality Index.
Figure 3Parallel mediation analysis. Path model showing the effect of Multiple Sclerosis Rating Scale—Revised (MSRS-R; measuring global MS symptom burden) on the Patient Health Questionnaire-9 (PHQ-9) score (measuring depression) as mediated simultaneously by Modified Fatigue Impact Scale-5 (MFIS-5; measuring fatigue) and Pittsburgh Sleep Quality Index (PSQI; measuring sleep quality). Path c represents the effect of MSRS-R on PHQ-9 without mediators in the model. Path c’ represents the effect of MSRS-R on PHQ-9 when MFIS-5 and PSQI mediators are included in the model. Paths a1b1 and a2b2 represent the effect of MSRS-R on PHQ-9 through MFIS-5 or PSQI respectively. The figure shows nonstandardized β regression coefficients (*P<.05, **P<.001, ***P<.0001) as reported by PROCESS Macro in SPSS [43]. MS: multiple sclerosis.
Figure 4Performance of the machine learning pipeline using all sensors and the best sensor combination for predicting each of the 4 clinically relevant outcomes in people with multiple sclerosis during a state-mandated stay-at-home period. "Accuracy (All Sensors)" and "F1 Score (All Sensors)" are the accuracy (× 0.01) and F1-score obtained by combining all 6 sensors. "Accuracy (Best Sensors)" and "F1 Score (Best Sensors)" are the accuracy (× 0.01) and F1-score obtained by the best combination of sensors. See Multimedia Appendix 1 for additional performance metrics of all models. MFIS-5: Modified Fatigue Impact Scale-5; MSR-R: Multiple Sclerosis Rating Scale—Revised; PHQ-9: Patient Health Questionnaire-9; PSQI: Pittsburgh Sleep Quality Index.